Lawrence F. Eichenfield, MD, Rady Children’s Hospital, San Diego, and University of California San Diego, San Diego, California; Diane Thiboutot, MD, Penn State University College of Medicine, Hershey, Pennsylvania; Alan Shalita, MD, SUNY Downstate Medical Center, Brooklyn, New York; Leonard Swinyer, MD, Dermatology Research Center, Salt Lake City, Utah; Emil Tanghetti, MD, Center for Dermatology and Laser Surgery, Sacramento, California; Eduardo Tschen, MD, Academic Dermatology Associates, Albuquerque, New Mexico; Lisa Parr, PharmD, Clinical Affairs Department, OMP, Inc., Long Beach, California Read the rest of this article »

Mark Bechtel, MD; Catherine Sanders, MS; Ann Bechtel, RN, BSN
The Ohio State University College of Medicine, Columbus, Ohio

Disclosure: Dr. Bechtel is a speaker for Amgen, Centocor, Genentech, and Abbott. Ms. Sanders and Ms. Bechtel report no relevant conflicts of interest.

Abstract
Biologic agents have been a significant advancement in the management of psoriasis. Along with significant clinical improvement, there have been concerns for emerging side effects with the use of biologics. Reports have emerged showing the association between efalizumab and the development of progressive multifocal leukoencephalopathy and other demyelinating disorders. Tumor necrosis factor-alpha inhibitors have been associated with various demyelinating disorders. As such, it is imperative for dermatologists to be well informed regarding how to notify patients about the risks of biologic treatment. Dermatologists must be able to identify the signs and symptoms of neurological complications and recognize when to refer patients to neurologists for diagnostic workup, disease confirmation, and any necessary treatment. This review is a compilation of evidence showing the association between biologic therapy and neurological complications, as well as an overview of the clinical presentation and diagnosis of such diseases.
(J Clin Aesthetic Dermatol. 2009;2(11):27–32.) Read the rest of this article »

Panta Rouhani, PhD, MPH, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida;Department of Epidemiology and Public Health, Miller School of Medicine, University of Miami, Miami, Florida; Robert S. Kirsner, MD, PhD, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida; Department of Epidemiology and Public Health, Miller School of Medicine, University of Miami, Miami, Florida; Antoine Amado, MD, Department of Dermatology, Cleveland Clinic, Cleveland, Ohio; Lora E. Fleming, MD, PhD, Department of Epidemiology and Public Health, Miller School of Medicine, University of Miami, Miami, Florida; Keyvan Nouri, MD, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida; Sharon E. Jacob, MD, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida; Division of Dermatology, University of California, San Diego, San Diego, California Read the rest of this article »

Richard G. Fried, MD, PhD, Clinical Director, Yardley Dermatology Associates, Yardley, Pennsylvania; Wm. Philip Werschler, MD, Assistant Clinical Professor of Medicine and Dermatology, University of Washington, Seattle, Washington; Tracy Floirendo, MA, Yardley Dermatology Associates, Yardley, Pennsylvania Read the rest of this article »

James Q. Del Rosso, DO, FAOCD; Grace K. Kim, DO

Introduction
Seborrheic dermatitis (SD) is a common inflammatory dermatoses that may affect infants, adolescents, and adults of all ethnicities and races.[1,2] SD exhibits two incidence peaks, one during infancy, and the other during the fourth to sixth decades of life.[3] The prevalence of SD ranges from 1 to 5 percent in the immunocompetent population and increases in the immunocompromised population, especially among patients with acquired immunodeficiency syndrome (AIDS).[2–4] Infantile SD occurs between the second and tenth week of life and peaks at three months of age.[4] Infantile SD is distinguished from adult or adolescent SD in that the infantile form is almost always confined to the first 3 to 12 months of life, while adult SD is characteristically chronic and relapsing throughout life.[5] SD can also present in association with other skin disorders, such as atopic dermatitis (AD), which can often create diagnostic confusion. In one study, 49 percent of children with AD between the ages of 2 to 12 months had a history of infantile SD as compared to 17 percent of controls.[4] SD has also been observed in conjunction with other skin diseases, such as rosacea (rosacea-seborrheic dermatitis overlap), blepharitis, acne vulgaris (AV), pityriasis versicolor, and Malassezia folliculitis.[6–9] Read the rest of this article »